BG Medicine, Inc. BGMD

BGMD Company Overview

BG Medicine, Inc. (formerly NASDAQ: BGMD) was a U.S.-based life sciences and diagnostics company focused on the development and commercialization of cardiovascular diagnostic tests and biomarker-based products. The company operated within the in vitro diagnostics and molecular diagnostics industries, with a primary emphasis on cardiovascular disease management, heart failure risk assessment, and personalized medicine applications. Its core commercial product was the BGM Galectin-3® test, a blood test designed to aid in assessing prognosis in patients with chronic heart failure.

The company’s principal revenue drivers historically included diagnostic product sales, licensing arrangements, and collaborations tied to biomarker discovery and clinical diagnostics. BG Medicine positioned itself around biomarker-based clinical decision support, leveraging proteomics and molecular analytics to identify disease indicators with potential clinical utility. The company was founded in the early 2000s and evolved from a biomarker discovery platform business into a more focused cardiovascular diagnostics enterprise. Public filings and industry reporting indicate that BG Medicine faced prolonged financial and commercialization challenges, and publicly available information regarding ongoing independent operations after the mid-2010s is limited. Data inconclusive based on available public sources regarding the company’s current operating status.